Abstract A10: Higher incidence of epigenomic alterations on BRAF and NRAS wild type melanoma brain metastases

Diego M. Marzese; Jamie L. Huynh; Sharon K. Huang; Garni Barkhoudarian; Daniel F. Kelly; Dave S.B. Hoon

doi:10.1158/1538-7445.BRAIN15-A10

Abstract A10: Higher incidence of epigenomic alterations on BRAF and NRAS wild type melanoma brain metastases

Diego M. Marzese
, Jamie L. Huynh
, Sharon K. Huang
, Garni Barkhoudarian
, Daniel F. Kelly
, Dave S.B. Hoon

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Research
Volume	75
DOIs	https://doi.org/10.1158/1538-7445.BRAIN15-A10
State	Published - Dec 1 2015

Disciplines

Genetics
Biology
Oncology

Access to Document

10.1158/1538-7445.BRAIN15-A10License: Unspecified

Cite this

@article{3985ac13e49543489b446df60c20ec44,

title = "Abstract A10: Higher incidence of epigenomic alterations on BRAF and NRAS wild type melanoma brain metastases",

author = "Marzese, \{Diego M.\} and Huynh, \{Jamie L.\} and Huang, \{Sharon K.\} and Garni Barkhoudarian and Kelly, \{Daniel F.\} and Hoon, \{Dave S.B.\}",

note = "Abstracts: AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC Combined BRAF and NRAS gene mutations (mt) account for 70-80\% of metastatic melanomas. Patients with BRAF mt benefit from novel targeted therapies; however, patients without this mutation lack effective targeted therapies.",

year = "2015",

month = dec,

day = "1",

doi = "10.1158/1538-7445.BRAIN15-A10",

language = "American English",

volume = "75",

journal = "Cancer Research",

}

TY - JOUR

T1 - Abstract A10: Higher incidence of epigenomic alterations on BRAF and NRAS wild type melanoma brain metastases

AU - Marzese, Diego M.

AU - Huynh, Jamie L.

AU - Huang, Sharon K.

AU - Barkhoudarian, Garni

AU - Kelly, Daniel F.

AU - Hoon, Dave S.B.

N1 - Abstracts: AACR Special Conference: Advances in Brain Cancer Research; May 27-30, 2015; Washington, DC Combined BRAF and NRAS gene mutations (mt) account for 70-80% of metastatic melanomas. Patients with BRAF mt benefit from novel targeted therapies; however, patients without this mutation lack effective targeted therapies.

PY - 2015/12/1

Y1 - 2015/12/1

UR - http://cancerres.aacrjournals.org/content/75/23_Supplement/A10

U2 - 10.1158/1538-7445.BRAIN15-A10

DO - 10.1158/1538-7445.BRAIN15-A10

M3 - Article

VL - 75

JO - Cancer Research

JF - Cancer Research

ER -

Abstract A10: Higher incidence of epigenomic alterations on BRAF and NRAS wild type melanoma brain metastases

Disciplines

Access to Document

Other files and links

Cite this